Endocrine Society GUIDELINES Bundle (free trial)

Metabolic Risk

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/302967

Contents of this Issue

Navigation

Page 6 of 17

7 HYPERLIPIDEMIA LDL-C ≥190 mg/dL or triglycerides ≥200 mg/dL: Evaluate for 2° causes. If ruled out, suspect 1° cause. High-intensity statins, fenofibrate MODERATE CVD RISK 10-year risk 5% to <7.5%: Moderate-intensity statin therapy with LDL goal of <130 mg/dL OR 30–50% reduction in primary prevention DYSLIPIDEMIA Low HDL and TG ≥200 mg/dL: Consider adding fenofibrate to statin HIGH CVD RISK 10-year risk ≥7.5%: High-intensity statin therapy with LDL-C goal of <100 mg/dL OR >50% reduction in primary prevention

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Metabolic Risk